Pinja Jalkanen

Pinja Jalkanen

Auto-generated profile, based on publicly available information

Pinja Jalkanen

Institute of Biomedicine, University of Turku, Turku, Finland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
PJPinja Jalkanen
Pinja Jalkanen
PKPekka Kolehmainen
Pekka Kolehmainen
HHHanni K. Häkkinen
Hanni K. Häkkinen
MHMoona Huttunen
Moona Huttunen
PTPaula A. Tähtinen
Paula A. Tähtinen
IJIlkka Julkunen
Ilkka Julkunen
As SARS-CoV-2 has been circulating for over a year, dozens of vaccine candidates are under development or in clinical use. The BNT162b2 mRNA COVID-19 vaccine induces spike protein-specific neutralizing antibodies associated with protective immunity. The emergence of the B.1.1.7 and B.1.351 variants has raised concerns of reduced vaccine efficacy and increased re-infection rates. Here we show, that after the second dose, the sera of BNT162b2-vaccinated health care workers (n = 180) effectively neutralize the SARS-CoV-2 variant with the D614G substitution and the B.1.1.7 variant, whereas the neutralization of the B.1.351 variant is five-fold reduced. Despite the reduction, 92% of the seronegative vaccinees have a neutralization titre of >20 for the B.1.351 variant indicating some protection. The vaccinees’ neutralization titres exceeded those of recovered non-hospitalized COVID-19 patients. Our work provides evidence that the second dose of the BNT162b2 vaccine induces cross-neutralization of at least some of the circulating SARS-CoV-2 variants.

5 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMilja Belik
Milja Belik
PJPinja Jalkanen
Pinja Jalkanen
RLRickard Lundberg
Rickard Lundberg
ARArttu Reinholm
Arttu Reinholm
LLLarissa Laine
Larissa Laine
IJIlkka Julkunen
Ilkka Julkunen
Two COVID-19 mRNA (of BNT162b2, mRNA-1273) and two adenovirus vector vaccines (ChAdOx1 and Janssen) are licensed in Europe, but optimization of regime and dosing is still ongoing. Here we show in health care workers (n = 328) that two doses of BNT162b2, mRNA-1273, or a combination of ChAdOx1 adenovirus vector and mRNA vaccines administrated with a long 12-week dose interval induce equally high levels of anti-SARS-CoV-2 spike antibodies and neutralizing antibodies against D614 and Delta variant. By contrast, two doses of BNT162b2 with a short 3-week interval induce 2-3-fold lower titers of neutralizing antibodies than those from the 12-week interval, yet a third BNT162b2 or mRNA-1273 booster dose increases the antibody levels 4-fold compared to the levels after the second dose, as well as induces neutralizing antibody against Omicron BA.1 variant. Our data thus indicates that a third COVID-19 mRNA vaccine may induce cross-protective neutralizing antibodies against multiple variants.

27 April 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
PJPinja Jalkanen
Pinja Jalkanen
PKPekka Kolehmainen
Pekka Kolehmainen
AHAnu Haveri
Anu Haveri
MHMoona Huttunen
Moona Huttunen
LLLarissa Laine
Larissa Laine
LKLaura Kakkola
Laura Kakkola
A decrease in vaccine efficacy against emerging SARS-CoV-2 variants has increased the importance of assessing the persistence of SARS-CoV-2 spike protein-specific antibodies and neutralizing antibodies. Our data show that after 6 months post two doses of BNT162b2 vaccine, antibody levels decrease yet remain detectable and capable of neutralizing emerging variants. By monitoring the vaccine-induced antibody responses, vaccination strategies and administration of booster doses can be optimized.

5 January 2022 in Research Square
Verified
Preprint
Open access
PDF file
MBMilja Belik
Milja Belik
PJPinja Jalkanen
Pinja Jalkanen
RLRickard Lundberg
Rickard Lundberg
ARArttu Reinholm
Arttu Reinholm
LLLarissa Laine
Larissa Laine
IJIlkka Julkunen
Ilkka Julkunen
Two COVID-19 mRNA and two adenovirus vector vaccines have been licensed in Europe and various vaccine combinations and dosing strategies have been exploited to maximize the immunity against COVID-19. Here, we show that among health care workers (n=328) two doses of BNT162b2, mRNA-1273, or ChAdOx1 as also a combination of an adenovirus vector and mRNA vaccines induces equally high levels of anti-SARS-CoV-2 spike antibodies and neutralizing antibodies against B.1 and B.1.617.2 when administrated with a long 12-week dose interval. Two doses of BNT162b2 with a short 3-week interval induce 2-3-fold lower titers of neutralizing antibodies compared to the long interval. Third mRNA vaccine dose for the short dose interval group increased the antibody levels 4-fold compared to the levels after the second dose. Importantly, sera from all three-times vaccinated neutralized B.1.1.529 (Omicron). The data indicates that a third COVID-19 mRNA vaccine dose efficiently induces cross-protective neutralizing antibodies against multiple variants.

30 July 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ASAnna Solastie
Anna Solastie
CVCamilla Virta
Camilla Virta
AHAnu Haveri
Anu Haveri
NENina Ekstrom
Nina Ekstrom
AKAnu Kantele
Anu Kantele
MMMerit Melin
Merit Melin
Background: Validation and standardization of accurate serological assays are crucial for the surveillance of the coronavirus disease 2019 (COVID-19) pandemic and population immunity. Methods: We describe the analytical and clinical performance of an in-house fluorescent multiplex immunoassay (FMIA) for simultaneous quantification of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein and spike glycoprotein. Furthermore, we calibrated IgG-FMIA against World Health Organisation (WHO) International Standard and compared FMIA results to an in-house enzyme immunoassay (EIA) and a microneutralisation test (MNT). We also compared the MNT results of two laboratories. Results: IgG-FMIA displayed 100% specificity and sensitivity for samples collected 13-150 days post-onset of symptoms (DPO). For IgA- and IgM-FMIA 100% specificity and sensitivity were obtained for a shorter time window (13-36 and 13-28 DPO for IgA- and IgM-FMIA, respectively). FMIA and EIA results displayed moderate to strong correlation, but FMIA was overall more specific and sensitive. IgG-FMIA identified 100% of samples with neutralising antibodies (NAbs). Anti-spike IgG concentrations correlated strongly (ρ=0.77-0.84, P <2.2×10 −16 ) with NAb titers. The NAb titers of the two laboratories displayed a very strong correlation (ρ=0.95, P <2.2×10 −16 ). Discussion: Our results indicate good correlation and concordance of antibody concentrations measured with different types of in-house SARS-CoV-2 antibody assays. Calibration against WHO international standard did not, however, improve the comparability of FMIA and EIA results.